Increase of antiretroviral therapy-associated cardiovascular risk;Incremento del riesgo cardiovascular asociado al tratamiento antirretroviral

Medicina Clinica

Volumn 122, Issue 19, 2004, Pages 746-747

  Estrada, Vicente ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

BODY FAT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; EDITORIAL; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MEDICAL LITERATURE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SPAIN; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 3142699484     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13062193     Document Type: Editorial

References (9)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-9.
2. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-7.
3. Leow MK, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003;88:1961-76.
4. Friis-Moller N, Sabin CA, Weber R, D'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
5. Ena J, Benito C, Llácer P, Pasquau F, Amador C. Distribución anormal de la grasa corporal y tipo de tratamiento antirretroviral como predictores de riesgo de enfermedad cardiovascular en pacientes infectados por el VIH. Med Clin (Barc) 2004;122:721-6.
6. Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003;88:1559-64.
7. Estrada V, Serrano-Ríos M, Martínez Larrad MT, Villar NG, González López A, Téllez MJ, et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:32-40.
8. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002;35:1219-30.
9. Rubio R, Berenguer J, Miró JM, Antela A, Iribarren JA, González J, et al. Actualización de las recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana (Marzo 2004) [consultado 07/03/2004]. Disponible en: www.gesidaseimc.com